Neotigason (Acitretin)

Acitretin, the active ingredient in Neotigason, is a retinoid presented as an oral tablet for systemic use. It is indicated for severe psoriasis and other disorders of keratinization, helping to normalize skin cell growth in adult patients.

GNH USA supplies Neotigason as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Neotigason (acitretin) is a systemic retinoid used to treat disorders of keratinization. - Severe psoriasis: reduces plaque formation, scaling and erythema. - Ichthyosis: improves skin barrier function and decreases scaling. - Other keratinization disorders: normalizes keratinocyte differentiation and limits hyperproliferation.

Acitretin may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Dry skin: increased transepidermal water loss. - Cheilitis: inflammation of the lips. - Hair loss: temporary alopecia. - Elevated liver enzymes: mild hepatic transaminase rise. - Hyperlipidemia: raised cholesterol or triglycerides. - Headache: mild to moderate intensity.

Serious or Rare Side Effects: - Severe hepatic injury: potential liver failure. - Pancreatitis: inflammation of the pancreas. - Depression or suicidal ideation: mood changes requiring monitoring. - Severe hypertriglyceridemia: risk of pancreatitis. - Bone abnormalities: premature epiphyseal closure in long‑term use. - Teratogenicity: birth defects if exposure occurs during pregnancy.

Neotigason requires careful monitoring and specific safety measures. - Pregnancy: contraindicated; teratogenic (Category X). - Women of childbearing potential: use effective contraception during treatment and for at least 3 years after discontinuation. - Liver function: monitor hepatic enzymes before and during therapy. - Lipid profile: assess triglycerides and cholesterol regularly. - Skeletal health: evaluate for bone changes during prolonged use. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Acitretin interacts with several medicines; some combinations should be avoided while others need close observation.

Major Interactions (Avoid): - Tetracyclines: increased risk of intracranial hypertension. - Vitamin A supplements: additive hypervitaminosis A. - Systemic steroids: reduced therapeutic efficacy. - Oral contraceptives: decreased contraceptive effectiveness. - Antifungal agents (e.g., ketoconazole): elevated acitretin plasma levels.

Moderate Interactions (Monitor Closely): - Warfarin: possible alteration of INR. - Phenytoin: hepatic enzyme induction may lower acitretin levels. - Statins: heightened risk of myopathy. - Beta‑blockers: potential skin reaction augmentation. - Methotrexate: combined hepatotoxicity risk.